Audit: QRS - Aniracetam for Health & Longevity

Audit conducted on 04/09/2026 13:31 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at_a_glance to ER Conclusion; protocol cells to ER Therapeutic Protocol; time cells to ER Practical Considerations and the Koliaki magnitude paragraph; benefits/risks to the ER tier headings; gates to Key Interactions & Contraindications; monitoring rows to the ER biomarker table verbatim.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	Cautious framing preserved: “without randomisation or a placebo group” (time_3_sub), “has no supporting rationale” (action_2_sub), and the Speculative tier retained for both benefits and risks.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications stay absolute (pregnancy and breastfeeding under Contraindications, not Key Interactions); “healthy adults going about ordinary life have never been tested” matches the ER wording without strengthening.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	No content from Benefit-Modifying Factors or Risk-Modifying Factors appears in the gates or the risks card; each gate item comes from the ER Key Interactions & Contraindications section.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names or NCT identifiers anywhere in the QRS; the only drug names used (perampanel, zopiclone, zolpidem, donepezil, rivastigmine, galantamine, morphine, tramadol, diphenhydramine, doxylamine, piracetam, oxiracetam, citicoline, choline bitartrate) are generic names drawn from the matching ER bullets.
1.6	The QRS does not introduce new attributions.	🟢	No source, organisation, or expert is credited anywhere in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Reserved, evidence-first register matching the ER; the ER’s own conclusion phrasing (“the evidence base is close to empty”) is carried through rather than recast.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	States dose, timing, thresholds, and monitoring targets so a decision can be made, without alarmist or promotional framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells describe the regimen used in the trials rather than issuing directions; participial constructions (“Split into two or three doses”, “Taken with dietary fat”) describe the dose rather than commanding the reader.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs directed at a reader; the only clinician reference is the fixed template footer disclaimer.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instance of “recommended”, “should”, “advised”, or “we suggest” in the QRS body.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	Verified mechanically: no occurrence of “you”, “your”, “we”, “our”, or “us” anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms are the ones the checklist requires preserved (Child-Pugh Class C, creatinine clearance, eGFR); Mini-Mental State Examination and Montreal Cognitive Assessment are written out rather than left as bare acronyms.
2.8	Information is presented in a concise and very compact manner	🟢	Benefits and risks are single semicolon-joined lines per tier; gate items are stripped to the key fact.
2.9	It DOES NOT address the reader directly	🟢	No second-person pronouns or reader-directed commands; confirmed by the same mechanical check as 2.6.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Content assumes a reader who will run a baseline panel, source a batch-tested product, and reassess against a pre-recorded cognitive score.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Six-marker baseline panel, 12-week and six-monthly retesting, and a four-month minimum course are presented without hedging on effort.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplification to a general-audience level; laboratory targets and severity thresholds are carried through intact.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance makes the audience-specific point explicitly — the trial signal sits in diagnosed memory disorders, and for an already healthy brain the evidence base is close to empty.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the file; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Formal register throughout: “sedative-hypnotics”, “centrally acting pain medications”, “hepatic impairment”, “gastrointestinal upset”; no consumer-grade substitutes.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: • Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment” • Gate headings: “Contraindications”, “Key Interactions” • Tier labels: “High”, “Medium”, “Low”, “Speculative” • Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present unmodified: “Protocol” (446), “Time to effect” (492), “Benefits” (542), “Risk & Side Effects” (599), “Monitoring” (623), “Qualitative Assessment” (723), “Contraindications” (567), “Key Interactions” (580), “Marker”/”Target”/”Why” (627–629); tier labels “Low: “/”Speculative: “ and “Medium: “/”Low: “/”Speculative: “ retained in the visible benefit and risk rows.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 38 template variable names are present (57 spans total after the sanctioned marker_# → marker_1..6 and qualitative_item_# → qualitative_item_1..5 expansions); the three non-variable “website=” spans are also intact.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A normalised structural diff against [qrs_template] shows no additions, removals, or reordering of non-variable markup; the head/style block is byte-identical apart from the title text.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section that maps into the QRS is empty — Expected Benefits, Potential Risks & Side Effects, Key Interactions & Contraindications, Therapeutic Protocol, Monitoring Protocol & Defining Success and Conclusion all carry content. Empty benefit and risk tiers are governed by 12.5 and 13.5, not by this item.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	action_1_label “Standard clinical protocol”, action_2_label “Best time of day”, action_3_label “Taken with dietary fat” are the ER bold labels verbatim, and “Alternative lower-dose protocol:” is preserved verbatim inside action_1_sub. Monitoring row labels match the ER biomarker column exactly.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	No invented labels; the time-to-effect cell labels are drawn from the ER’s own benefit headings and Koliaki endpoint wording rather than coined.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points anywhere in the file; the ER’s “⚠️ Conflicted” marker on the first Low benefit was correctly dropped. Tier emphasis is carried by the CSS classes and the bold tier labels.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Within budget: 3 protocol cells, 3 time cells, 2 benefit lines, 3 risk lines, 6 contraindications, 7 interactions, 6 monitoring rows, 5 qualitative items; drug example lists were trimmed rather than allowed to overflow.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at lines 2–14, immediately after “<!doctype html>” on line 1 and before the template comment on line 16.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” on line 3, closing “—” on line 13; the preceding “QRS — Metadata (invisible, parsed by audit tooling)” text is permitted.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated by any element in the head or body.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	All values trimmed; only duration: "00:03" is quoted, which is required because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: aniracetam_2026-0904-1151_Opus_ER.md, matching the ER’s own filename frontmatter value.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the version badge at the top of QRS.md.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0904-1324, correctly formatted.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version number, no additional qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9: qrs_filename: aniracetam_2026-0904-1151_Opus_QRS.html, matching the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys plus git_user and git_issue; no stray whitespace and no unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Aniracetam for Health & Longevity - Quick Reference Sheet”; matches the ER canonical_topic with the ampersand entity-encoded.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Aniracetam for Health & Longevity”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/04/2026”, correctly derived from qrs_creation_date: 2026-0904-1324.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”, matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	The header carries only the title and the template’s fixed subline; the ER’s “Also known as” list (Ro 13-5057, Ampamet, Draganon, and others) was correctly not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all four ER conclusion paragraphs — mechanism, the divided trial record, the supply hazard, and the verdict for a healthy brain — into one decision-shaped passage.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to a separate ER Conclusion sentence: fat-soluble compound holding excitatory signalling open; trials pointing in opposite directions; nothing tested in healthy adults going about ordinary life; supply as the larger hazard with labels often wrong; evidence base close to empty.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms and no classification terms; the descriptive phrases used (“fat-soluble”, “laboratory-made”, “excitatory signalling open a little longer”) are the ER’s own plain-language rendering and carry an everyday cognate.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No author names, years, sample sizes, or p-values; trials are referred to only collectively.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear in the at-a-glance text.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items come from the ER’s “Populations who should avoid Aniracetam:” list in that section.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete one-to-one coverage of the ER list: epilepsy/prior seizure/perampanel, pregnancy and breastfeeding, severe hepatic impairment, severe renal impairment, moderate-to-severe dementia, under 18.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six separate <li> elements at lines 570–575 inside the stop_items span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s trailing rationales were all stripped (“on the basis of absent human reproductive data”, “since hepatic hydrolysis is the only clearance route”, “where metabolite accumulation is documented”, “the group in which no benefit was seen and confusion was observed”, “for whom no human data of any kind exist”); no dash-trailing clauses remain.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All three ER parentheticals preserved verbatim: “(Child-Pugh Class C)”, “(creatinine clearance below 30 mL/min)”, “(Mini-Mental State Examination below 15)”.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses anywhere in Key Interactions & Contraindications.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six populations that should avoid the intervention, and the section is correctly populated rather than left empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state comment is required.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items are ER interaction bullets from that section, in ER order.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Seven of the ER’s interaction bullets are carried; the glutamate-blocking antiseizure bullet is correctly excluded because perampanel is already a contraindication, and the “Other interventions” bullet is correctly omitted because it records absence of interaction rather than an interaction.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven separate <li> elements at lines 583–589 inside the caution_items span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER severity tag (“Monitor”, “Caution”), mechanism sentence, and “Mitigation is…” clause was stripped; only the agent class plus its example list remains, with no dash-trailing content.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All seven parenthetical drug lists preserved; two were trimmed rather than dropped for the one-page budget — caffeine products kept “(caffeine tablets, energy formulations)” and racetams kept “(piracetam, oxiracetam)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER’s interaction parentheticals are plain comma-separated drug lists with no ranking symbols.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER identifies eight interaction bullets, and the section is correctly populated rather than left empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty, so no empty-state comment is required.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from the ER Therapeutic Protocol bullets.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose and duration, time of day, and co-administration with dietary fat are the three decision-bearing aspects; the ER’s remaining bullets are either non-actionable (“Origin of each approach”, “Sex-based differences: None established”) or folded into the selected cells.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so all three sets are used and no set needed to be emptied.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans populated: “Standard clinical protocol” / “1,500 mg daily by mouth” with the split-dosing, four-month minimum and the alternative 400–750 mg schedule; “Best time of day” / “Morning and early afternoon”; “Taken with dietary fat” / “With a fat-containing meal”.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	The ER supplies exactly three time-anchored readouts, and all three are used: 2–6 months for symptom improvement, 3 months for emotional state, and 6–12 months for maintained neuropsychological parameters.
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Order follows the ER’s own Low-tier benefit order: cognitive and behavioural symptoms first, then mood and emotional stability, then the longer-horizon cognitive and functional stability from the same open-label dataset.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	Three distinct time-to-effect aspects exist in the ER, so all three sets are used and none needed to be emptied.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans populated and traceable: time_1_sub is the ER Practical Considerations sentence; time_2_sub and time_3_sub come from the Koliaki magnitude paragraph in Expected Benefits.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Both populated tiers reproduce the ER Expected Benefits sub-headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 544–560.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the four Low and four Speculative headings appear, semicolon-separated; every “Magnitude:” paragraph, patient count, and mechanism sentence was dropped.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in either benefits row.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No benefit reaches High” and “No benefit reaches Medium”; both spans are correctly emptied and set to style="display: none" (lines 544–545) rather than carrying empty-state text.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All three populated tiers reproduce the ER Potential Risks & Side Effects sub-headings.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 601–617.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Headings only: one Medium, two Low, four Speculative; the discontinuation counts, the 502 mg assay figure, and the animal-model rationales were all dropped.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risks row.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER states “No risk reaches High”; the risks_high span is correctly emptied and set to style="display: none" (line 601).

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	All rows come from the ER Monitoring Protocol & Defining Success biomarker table.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All six ER biomarkers present with matching targets: MoCA 26–30 of 30, ALT 10–26 U/L, AST 10–26 U/L, eGFR 90 mL/min/1.73 m² or above, Vitamin B12 500–900 pg/mL, TSH 0.5–2.0 mIU/L.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Lines 713–717 carry the full ER cadence: baseline panel before the first dose, cognitive scale and liver enzymes at 12 weeks then every six months, eGFR annually.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All five items come from the ER’s qualitative-marker list in Monitoring Protocol & Defining Success.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five present: word-finding fluency, time to settle into focused work, emotional evenness, sleep onset latency and night awakenings, and absence of new confusion/agitation/twitching; the ER’s trailing rationale clauses were correctly stripped.

Issues 04/09/2026 13:31

Pass rate 100.00%. No issues found.